🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
41Score
DipBuster Score™
$101.66
+$0.98 (+0.97%)
Live price · Source: Yahoo
52-Week Position
$81.97
35% of range
$137.49
Beta
0.607
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.607
52W High$137.49
52W Low$81.97
DipBuster Brief
Key signals at a glance
Zone: Buy Zone
Neutral
Mid-Range Position (35% of 52-Week Range)
The stock sits in the middle of its annual range — no extreme dip opportunity, but also not overextended.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position35% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.607
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Abbott Laboratories (ABT), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-06-30 | Ahuja Nita | BUY | 347 |
| 2026-06-30 | Gonzalez Patricia Paola | BUY | 363 |
| 2026-06-30 | Morrone Louis H. | SELL | 269 |
| 2026-06-30 | Roman Michael F | BUY | 416 |
| 2026-06-30 | Stratton John G | BUY | 432 |
| 2026-06-30 | Conroy Kevin T | BUY | 231 |
| 2026-05-07 | Stratton John G | BUY | 2,000 |
| 2026-04-28 | Moreland Mary K | BUY | 5,314 |
| 2026-04-27 | Starks Daniel J | BUY | 10,000 |
| 2026-04-24 | Ahuja Nita | BUY | 2,286 |
Valuation
P/E RatioN/A
Market CapN/A
Beta0.607
Dividend/yrNone
52W High$137.49
52W Low$81.97
52-Week Range
$81.97Now$137.49
35% through annual range
From 52W High−26.1%
From 52W Low+24%
📖 Plain English Summary
Abbott Laboratories is at 35% of its 52-week range. Beta 0.607 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for ABT
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — ABT
Heuristic · balance sheet, insider filings, price data, academic research
Abbott Laboratories — DipBuster Score 41/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Abbott Laboratories free
Add ABT to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Freetrade
Simple investing app. Free ISA. UK and US stocks. FCA regulated.
Free share when you fund your account
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
26/25
Momentum & Volume
10/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
36
/100 · NEUTRAL
dip depth
22/25
oversold rsi
0/25
mean reversion
0/15
insider zone
14/25
capitulation
0/10
Insiders' avg buy price: $102.39 — marked 🟡 on the chart above.
Technical signal only. Not financial advice.
Quick Take
🟡
Watch
DipBuster Score: 41/100
📊
Run a full check in the AI analysis tab for a deeper look.
Company Profile
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The…
Sector
Healthcare
Market
🇺🇸 US
CEO
Robert Ford
Staff
114,000 employees
Website